2024-01-02
We are excited to announce that PolTREG will be attending the Biotech Showcase during J.P. Morgan Healthcare Week 2024 in San Francisco, from January 8 to 11.
Meet CEO Prof. Piotr Trzonkowski and Chief Business Officer Mariusz Jabłoński to discuss PolTREG’s cutting-edge technology in Treg cell therapies as a promising new form of personalized treatment for a wide range of autoimmune diseases.
Let’s connect!
2024-04-05
PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treatedwith its Treg therapy in combination with rituximab
2024-03-11
PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellulartherapies from the Chief Pharmaceutical Inspectorate in Poland.
2024-02-21
PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones
2024-02-07
Global institutional investors and investment funds hold over 25% of PolTREG’s shares.
2024-01-30
Prof. Piotr Trzonkowski co-authors peer-reviewed article showing scientific progress in T-regautoimmune therapy
2024-01-16
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes